Franklin Parlapiano Turner & Welch LLC trimmed its holdings in Novartis AG (NYSE:NVS – Free Report) by 0.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,244 shares of the company’s stock after selling 233 shares during the period. Novartis comprises about 2.2% of Franklin Parlapiano Turner & Welch LLC’s investment portfolio, making the stock its 16th biggest position. Franklin Parlapiano Turner & Welch LLC’s holdings in Novartis were worth $8,655,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its position in shares of Novartis by 23.1% during the second quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock worth $788,626,000 after acquiring an additional 1,389,610 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Novartis by 191.1% during the second quarter. Bank of New York Mellon Corp now owns 1,904,664 shares of the company’s stock valued at $202,771,000 after purchasing an additional 1,250,318 shares in the last quarter. Magnetar Financial LLC increased its holdings in shares of Novartis by 53.7% in the first quarter. Magnetar Financial LLC now owns 1,906,046 shares of the company’s stock worth $184,372,000 after purchasing an additional 666,104 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Novartis in the second quarter worth about $64,610,000. Finally, Mondrian Investment Partners LTD boosted its stake in Novartis by 40.1% during the first quarter. Mondrian Investment Partners LTD now owns 2,065,739 shares of the company’s stock valued at $199,819,000 after buying an additional 590,830 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.
Novartis Stock Down 0.2 %
Shares of NYSE:NVS opened at $114.06 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. The business has a 50 day simple moving average of $116.44 and a two-hundred day simple moving average of $108.39. Novartis AG has a 1 year low of $92.19 and a 1 year high of $120.92. The firm has a market capitalization of $233.14 billion, a PE ratio of 14.46, a price-to-earnings-growth ratio of 1.70 and a beta of 0.57.
Analysts Set New Price Targets
Get Our Latest Analysis on NVS
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Recommended Stories
- Five stocks we like better than Novartis
- ESG Stocks, What Investors Should Know
- WD-40 Company Gears Up for a Double-Digit Stock Advance
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Monster and Celsius Energized: Which Stock Offers More Upside?
- Manufacturing Stocks Investing
- Sherwin-Williams Plunges Into Buying Opportunity: Time to Buy?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.